Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
ACADEMIA As Kisunla Approval Nears, Japanese Alzheimer’s KOL Hails Increase in Options
August 9, 2024
-
REGULATORY Chuikyo Disappointed over Industry Survey on 2024 Drug Pricing Reform
August 8, 2024
-
REGULATORY Novartis’ Fabhalta, UCB’s Briviact and More to Join NHI Price List on Aug. 15
August 8, 2024
-
REGULATORY Dupixent Braces for Third Re-Pricing, LEO/Lilly Meds Face Spillover Cuts
August 8, 2024
-
REGULATORY AstraZeneca’s Tezspire to Face 4.1% CEA Price Cut in November
August 8, 2024
-
BUSINESS NCC Offshoot’s 1st CAR-T Therapy Set to Enter Clinic Next Year: CEO
August 7, 2024
-
COMMENTARY Analysis: All Eyes Riveted on FY2024 Drug Price Survey for Off-Year Revision
August 6, 2024
-
BUSINESS Japan Major Pharmas Endure Market Crash, but Biotechs Take a Hit
August 6, 2024
-
BUSINESS Eisai Stands Firmly Behind Leqembi Profile despite EU Rejection
August 5, 2024
-
REGULATORY Lilly’s Alzheimer’s Med Donanemab Now in Line for Japan Approval
August 2, 2024
-
REGULATORY Nitrosamine Self-Inspection Deadline Extended to Aug. 1 amid Challenges
August 1, 2024
-
BUSINESS Sumitomo Announces Its Largest-Yet Job Cut of 700 Employees in Japan
August 1, 2024
-
REGULATORY Japan Aspires to Double Private Investments in Pharma Startups over 5 Years
July 31, 2024
-
BUSINESS Recordati Japan on Hunt for Rare Disease Assets at Risk of Drug Loss
July 30, 2024
-
BUSINESS Mitsubishi Tanabe to Launch Voluntary Buyout Program
July 30, 2024
-
BUSINESS EU Regulator Rejects Leqembi, Eisai to Seek Re-Examination
July 29, 2024
-
BUSINESS Takeda Will Stage Recovery at Home after 4 Drug Launches in FY2024: Japan Head
July 26, 2024
-
BUSINESS Global Pharma Market Grows Double Digit in 2023, Humira Stays Atop Drug Ranking: IQVIA
July 26, 2024
-
ORGANIZATION Japan Logs 10th Consecutive Year of Decrease in Drug Reps, Hefty Dip in 2023
July 25, 2024
-
BUSINESS Nichi-Iko to Join Forces with Kyowa in Generic Production, Eyeing Reorganization
July 24, 2024
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…